Clarification19 Jan 2026, 12:48 pm
Sun Pharma Denies 'Speculative' USD 10 Billion Organon Acquisition News
AI Summary
In response to a rumour verification letter from BSE, Sun Pharmaceutical Industries Ltd clarified that the news item captioned 'Sun Pharma Eyes Stronger US Presence with USD 10 Billion Organon Acquisition' is speculative in nature. The company stated that there is no material event or information that requires disclosure under Regulation 30 of the Listing Regulations. Sun Pharma adheres to the highest standards of governance and disclosures and will keep the stock exchanges informed of any material events as required.
Key Highlights
- Sun Pharma denies the news of a USD 10 Billion Organon Acquisition
- The news is speculative and there is no material event or information requiring disclosure
- Sun Pharma maintains high standards of governance and disclosures
- The company will inform stock exchanges of any material events as required